-
公开(公告)号：US20190225673A1
公开(公告)日：2019-07-25
申请号：US16334706
申请日：2017-09-29
摘要： Embodiments of the disclosure include methods and compositions for treatment of a medical condition related to the liver, including at least viral infections and liver cancer, for example. In specific embodiments, immunotherapies are provided for delivering polynucleotides locally to the liver, wherein the polynucleotides encode particular gene products that include bispecific antibodies, including those that target certain liver antigens, for example.
-
公开(公告)号：US20190117692A1
公开(公告)日：2019-04-25
申请号：US16109615
申请日：2018-08-22
发明人： Stephen M. G. Gottschalk , Xiao-Tong Song , Kota Iwahori , Mireya Paulina Velasquez , Stewart Abbot
IPC分类号： A61K35/17 , C07K16/28 , C07K16/46 , A61K39/00 , C12N5/0783 , C07K16/30 , A61K45/06 , A61N5/10 , C07K16/40 , A61K39/395
摘要： Embodiments concern methods and/or compositions related to immunotherapy for cancer. In particular embodiments, engager immune cells harbor a vector that encodes a secretable engager molecule. In particular cases, the engager molecule has an activation domain and an antigen recognition domain. In some embodiments, the engager molecules further comprise a cytokine or co-stimulatory domain, for example.
-
公开(公告)号：US12102652B2
公开(公告)日：2024-10-01
申请号：US16326270
申请日：2017-08-11
IPC分类号： C07K14/715 , A61K35/12 , A61K35/17 , A61K39/00 , A61P35/00 , C07K14/00 , C07K14/47 , C07K14/725 , C12N15/85 , A61K38/00
CPC分类号： A61K35/17 , A61K35/12 , A61K39/001119 , A61P35/00 , C07K14/00 , C07K14/4748 , C07K14/7051 , C07K14/715 , C07K14/7155 , C12N15/85 , A61K38/00
摘要： Embodiments of the disclosure include methods and compositions for enhancing expansion of immune cells for immunotherapy. In particular embodiments, immune cells, such as T-cells, express a constitutively active cytokine receptor in which the transmembrane and endodomains are able to provide an activating signal separately from any input to the corresponding exodomain to which they are operably linked. In specific embodiments, the transmembrane and endodomain from IL-7Rα is utilized with the exodomain of CD34.
-
公开(公告)号：US20160015749A1
公开(公告)日：2016-01-21
申请号：US14773327
申请日：2014-03-05
发明人： Stephen M. G. Gottschalk , Xiao-Tong Song , Kota Iwahori , Mireya Paulina Velasquez , Stewart Abbot
IPC分类号： A61K35/17 , C07K16/28 , A61N5/10 , C07K16/40 , A61K39/395 , A61K45/06 , C12N5/0783 , C07K16/30
CPC分类号： A61K35/17 , A61K39/0011 , A61K39/39558 , A61K45/06 , A61K2039/5156 , A61K2039/5158 , A61N5/10 , C07K16/2803 , C07K16/2809 , C07K16/2866 , C07K16/30 , C07K16/40 , C07K16/468 , C07K2317/14 , C07K2317/31 , C07K2317/622 , C12N5/0636 , C12N2501/50 , C12N2501/599 , C12N2510/00
摘要： Embodiments concern methods and/or compositions related to immunotherapy for cancer. In particular embodiments, engager immune cells harbor a vector that encodes a secretable engager molecule. In particular cases, the engager molecule has an activation domain and an antigen recognition domain. In some embodiments, the engager molecules further comprise a cytokine or co-stimulatory domain, for example.
摘要翻译： 实施方案涉及与癌症免疫治疗相关的方法和/或组合物。 在具体实施方案中，引入免疫细胞具有编码可分泌的融合子分子的载体。 在特定情况下，诱导分子具有活化结构域和抗原识别结构域。 在一些实施方案中，合并分子还包含例如细胞因子或共刺激结构域。
-
公开(公告)号：US20160000842A1
公开(公告)日：2016-01-07
申请号：US14770061
申请日：2014-03-05
IPC分类号： A61K35/768 , A61K45/06 , C07K16/32 , C12N7/00 , C07K16/28
CPC分类号： A61K35/768 , A61K35/76 , A61K38/1764 , A61K38/1774 , A61K45/06 , C07K16/2803 , C07K16/30 , C07K16/32 , C07K2317/10 , C07K2317/31 , C07K2317/622 , C12N7/00 , C12N2710/24121 , C12N2710/24132 , C12N2710/24143 , Y02A50/465 , A61K2300/00
摘要： Embodiments of the present disclosure concern oncolytic viruses, such as vaccinia virus, for example, for the treatment of cancer, wherein the viruses encode an engager molecule having an activation domain that recognizes a cell molecule, such as CD3, for example, on T cells and an antigen recognition domain that recognizes a tumor antigen, such as EphA2, HER2, GD2, or Glypican-3, for example. In some embodiments, the engager molecules further comprise a cytokine or co-stimulatory domain, for example. Methods of treating cancer using one or more of the compositions are encompassed in the disclosure.
摘要翻译： 本公开的实施方案涉及溶瘤病毒，例如痘苗病毒，例如用于治疗癌症，其中所述病毒编码具有识别例如CD3的细胞分子例如CD3的细胞分子的活化区的融合分子 以及例如识别肿瘤抗原的抗原识别结构域，例如EphA2，HER2，GD2或磷脂酰肌醇蛋白聚糖-3。 在一些实施方案中，合并分子还包含例如细胞因子或共刺激结构域。 使用一种或多种组合物治疗癌症的方法包括在本公开中。
-
公开(公告)号：US11566063B2
公开(公告)日：2023-01-31
申请号：US16334706
申请日：2017-09-29
摘要： Embodiments of the disclosure include methods and compositions for treatment of a medical condition related to the liver, including at least viral infections and liver cancer, for example. In specific embodiments, immunotherapies are provided for delivering polynucleotides locally to the liver, wherein the polynucleotides encode particular gene products that include bispecific antibodies, including those that target certain liver antigens, for example.
-
公开(公告)号：US20180079824A1
公开(公告)日：2018-03-22
申请号：US15558596
申请日：2016-03-18
IPC分类号： C07K16/32 , C07K14/705 , C12N5/0783 , A61K35/17 , A61K45/06 , C07K14/725
CPC分类号： C07K16/32 , A61K35/17 , A61K45/06 , C07K14/7051 , C07K14/70521 , C07K2317/622 , C07K2319/03 , C07K2319/74 , C12N5/0636 , C12N2510/00 , C12N2740/13043
摘要： Embodiments of the disclosure include immune cells expressing HER2-specific chimeric antigen receptors (CAR) and treatment of cancer therewith. In specific embodiments, sarcoma or glioblastoma are treated. In specific embodiments, such as for glioblastoma, for example, T-cells expressing a HER2-specific CAR are pp65CMV-specific T cells.
-
公开(公告)号：US20170281683A1
公开(公告)日：2017-10-05
申请号：US15513900
申请日：2015-09-25
IPC分类号： A61K35/17 , C12N5/0783 , C07K16/28 , C07K14/705 , C07K16/30
CPC分类号： A61K35/17 , A61K2039/505 , A61P35/00 , C07K14/70521 , C07K14/70578 , C07K16/28 , C07K16/303 , C07K2317/622 , C07K2317/76 , C07K2319/03 , C07K2319/74 , C12N5/0637 , C12N5/0638 , C12N5/0646 , C12N2510/00
摘要： Embodiments of the disclosure include methods and compositions related to immunotherapy that targets glypican-3. In particular embodiments, immune cells engineered to comprise a chimeric antigen receptor that targets glypican-3 are contemplated, and uses thereof. In particular embodiments, medical conditions that are associated with glypican-3 expression or an overexpression of glypican-3 are treated with GPC3 CARs.
-
公开(公告)号：US20160015750A1
公开(公告)日：2016-01-21
申请号：US14773434
申请日：2014-03-10
发明人： Stephen M. G. Gottschalk , LaTerrica C. Williams , Tiara T. Byrd , Nabil M. Ahmed , Xiao-Tong Song
IPC分类号： A61K35/17 , C07K14/725 , C07K14/705
CPC分类号： A61K35/17 , A61K2035/124 , A61K2039/505 , C07K14/7051 , C07K14/70521 , C07K14/70578 , C07K16/2851 , C07K16/30 , C07K2319/00 , C12N15/62
摘要： Embodiments of the invention provide for cell therapy for cancers having a TEM1 or TEM8 antigen. Certain embodiments provide for cell therapy that targets tumor vasculature, including the tumor vascular bed, for example. In specific embodiments, TEM1- and/or TEM8-specific chimeric antigen receptors are employed.
摘要翻译： 本发明的实施方案提供具有TEM1或TEM8抗原的癌症的细胞疗法。 某些实施例提供靶向肿瘤脉管系统的细胞疗法，例如包括肿瘤血管床。 在具体实施方案中，使用TEM1-和/或TEM8特异性嵌合抗原受体。
-
公开(公告)号：US11219646B2
公开(公告)日：2022-01-11
申请号：US16334712
申请日：2017-09-29
IPC分类号： A61K35/17 , A61P1/16 , A61P31/20 , C07K14/725 , C07K14/705 , C07K16/08 , C12N15/11
摘要： Embodiments of the disclosure encompass immunotherapy for Hepatitis B viral (HBV) infection in an individual in need thereof. The immunotherapy comprises one or more chimeric antigen receptors (CAR) that target a HBV antigen, including CAR molecules that utilize specific scFv antibodies. In certain cases, the CAR comprises one or more mutations to reduce binding to Fc receptors. In specific aspects, cells that express the CAR(s) have reduced cytotoxicity that is safer and/or beneficial to individuals that are immunocompromised.
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.023 秒)
